Highlights the inadequacies of current antianginal therapies and the need for novel metabolic modulators to improve symptom control and quality of life.
Current therapies often inadequate for angina; hypothesis-generating for metabolic modulators but requires randomized trials before adoption.
Chronic angina is a major medical problem in the United States with more than 6 million patients affected, a number that will increase substantially because of the progressive aging of the population. The annual mortality rate for patients with chronic angina is approximately 2%, but is much higher in certain subsets of patients, particularly the elderly. Angina is also associated with major social and economic burdens. Because of poor symptom control and hemodynamic, as well as other drug side effects, angina is commonly associated with a poor quality of life. No new class of drug has been available for angina treatment in more than two decades, and current medications frequently fail to provide adequate symptom control. Thus, the majority of patients are taking two or three antianginal medications. New agents that modulate myocardial metabolism have shown antianginal efficacy, a favorable side-effect profile, and an absence of hemodynamic effects.
No takes yet. Share an insight, caveat, or question.
John O. Parker (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: